Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Nathan H. Fowler, MD; Felipe Samaniego, MD; Wojciech Jurczak, MD, PhD; Nilanjun Ghosh, MD, PhD; Enrico Derenzini, MD; James A. Reeves, MD; Wanda Knopinska-Posluszny, MD; Chan Y. Cheah, DMSc; Tycel Phillips, MD; Ewa Lech-Maranda, MD, PhD; Bruce D. Cheson, MD; Paolo F. Caimi, MD; Sebastian Grosicki, MD, PhD; Lori A. Leslie, MD; Julio C. Chavez, MD; Gustavo Fonseca, MD; Sunil Babu, MD; Daniel J. Hodson, MD; Spencer H. Shao, MD; John M. Burke, MD; Jeff P. Sharman, MD; Jennie Y. Law, MD; John M. Pagel, MD, PhD; Hari P. Miskin, MSc; Peter Sportelli, BS; Owen A. O’Connor, MD, PhD; Michael S. Weiss, JD; and Pier Luigi Zinzani, MD, PhD

PURPOSE
Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term tolerability and toxicity, which interfere with continuous use. Umbralisib, a dual inhibitor of PI3Kδ/casein kinase-1ε, exhibits improved selectivity for PI3Kδ compared with other PI3K inhibitors. This phase IIb trial was designed to evaluate the efficacy and safety of umbralisib in patients with R/R iNHL.

PATIENTS AND METHODS
In this multicohort, open-label, phase IIb study, 208 patients with R/R marginal zone, follicular, or small lymphocytic lymphoma (MZL, FL, or SLL) unresponsive to prior treatments (1 MZL; ≥ 2 FL/SLL), including ≥ 1 anti-CD20–based therapy, were administered umbralisib 800 mg orally once daily until disease progression, unacceptable toxicity, or study withdrawal. Primary end point is overall response rate; secondary end points include time to response, duration of response, progression-free survival, and safety.

RESULTS
The median follow-up is 27.7 months (efficacy) and 21.4 months (safety). The overall response rate was 47.1%, and tumor reduction occurred in 86.4% of patients. The median time to response was 2.7-4.6 months. The median duration of response was not reached for MZL, 11.1 months for FL, and 18.3 months for SLL. Median progression-free survival was not reached for MZL, 10.6 months for FL, and 20.9 months for SLL. At least one grade ≥ 3 treatment-emergent adverse event (TEAE) was reported in 53.4% of patients. TEAEs led to umbralisib discontinuation in 32 patients (15.4%). A total of 31 patients (14.9%) discontinued because of a treatment-related adverse event. Grade ≥ 3 TEAEs reported in ≥ 10% of patients: neutropenia (11.5%) and diarrhea (10.1%). Increased ALT/AST (grade ≥ 3) occurred in 6.7%/7.2% of patients.

CONCLUSION
Umbralisib achieved meaningful clinical activity in heavily pretreated patients with iNHL. The safety profile was manageable, with a relatively low incidence of immune-mediated toxicities and adverse event–related discontinuations.

J Clin Oncol 39:1609-1618. © 2021 by American Society of Clinical Oncology

INTRODUCTION
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of mature B-cell neoplasms.1,3 In the United States, NHL is the seventh most commonly diagnosed cancer and the most prevalent hematologic malignancy, with an estimated 77,240 new cases and 19,940 associated deaths in 2020.4,6 These lymphomas are generally classified as either indolent NHL (iNHL) or aggressive. Common iNHL subtypes include marginal zone, follicular, and small lymphocytic lymphoma (MZL, FL, and SLL).1,3 Management is usually tailored according to clinical presentation and patient characteristics. Although anti-CD20 therapy alone or in combination is standard in untreated patients, little consensus exists for patients with relapsed disease.6-9 Several treatment options available for subsequent relapses include chemotherapy and targeted agents with or without anti-CD20–directed immunotherapy. However, successive relapses are associated with declining response rates, shorter remission times, and increased cumulative toxicity risk.10-13 The phosphatidylinositol-3-kinase (PI3K) inhibitor drug class has emerged for treatment of relapsed B-cell malignancies. A dysregulated PI3K signaling pathway may drive abnormal cellular programming that characterizes malignant B cells. In particular, the...
CONTEXT

Key Objective
Convenient, safe, and effective new drugs can afford unprecedented opportunities to manage indolent lymphomas as a chronic disease, without the need for reliance on chemotherapy. Umbralisib is a unique, potent, oral, once-daily, dual inhibitor of phosphatidylinositol-3-kinase δ-isofrom and casein kinase-1ε, which has demonstrated efficacy and safety as a single agent and in combination, and may offer a novel nonchemotherapy treatment option for patients with relapsed or refractory disease.

Knowledge Generated
UNITY-NHL is a multicenter trial investigating umbralisib monotherapy in patients with relapsed or refractory marginal zone, follicular, and small lymphocytic lymphomas. These data reveal that umbralisib is associated with a manageable toxicity profile, leading to low rates of drug discontinuation and clinically meaningful efficacy in a heavily treated population.

Relevance
Available targeted treatment options for patients with relapsed or refractory disease are limited and associated with treatment-limiting toxicities. These data demonstrate that umbralisib may provide a novel targeted treatment option for previously treated patients with indolent lymphomas.

δ-isofrom (PI3Kδ), with expression restricted to cells of hematopoietic origin, is highly expressed in leukocytes and plays an essential role in B-cell development, survival, and function.14-16 Several PI3K inhibitors have shown efficacy as monotherapy in the treatment of relapsed or refractory (R/R) iNHL,11,17,18 with overall response rates (ORRs) ranging from 43.7% to 57%.11,17,18 Despite the activity of existing PI3K inhibitors, high discontinuation rates because of toxicities limit their use.11,17,18 Common serious adverse events (SAEs) include infections, hyperglycemia, transaminitis, diarrhea and/or colitis, and other immune-mediated toxicities (eg, pneumonitis).17,19-22 Although the mechanistic basis for the toxicities observed with first-generation PI3K inhibitors is not fully understood, the differential PI3K-isofrom inhibition profiles of each agent23 and other specific pharmacologic properties have been implicated.24,25 For example, hyperglycemia is associated with PI3Kα inhibition,26 whereas hematologic and immune-mediated toxicities are attributed to PI3Kβ/γ inhibition.25

Umbralisib is a novel dual inhibitor of PI3Kδ and casein kinase-1ε (CK1ε), with no known clinically relevant drug-drug interactions.24,27-29 Compared with other approved PI3K inhibitors, umbralisib has a unique chemical structure, and preclinical analysis demonstrated potent PI3Kδ isofrom inhibition at clinically achievable concentrations. Umbralisib exhibits more than 1,500-fold greater selectivity (Kd) for PI3Kδ over the α- and β-isofroms and approximately 225-times greater selectivity over the γ-isofrom.24 PI3Kγ functions as a molecular switch between immune stimulation and suppression and, when inhibited, increases inflammation.20 In preclinical models, the loss of PI3Kδ alone was not sufficient to result in autoimmunity.31,32 However, combined loss of PI3Kγ and PI3Kδ in T cells results in severe autoimmunity and inflammation,33 suggesting that the lack of PI3Kγ inhibition by umbralisib may be advantageous.

Additionally, umbralisib is unique in that it inhibits CK1ε.29,34 This enzyme plays a pivotal role in protein translation of oncogenes (ie, MYC, BCL2, and CCND1) and has been shown to regulate elements of the β-catenin/wingless-type MMTV integration site (WNT) signaling pathway, which may influence the immunomodulatory effects of T cells.29,34,35 Therefore, improved isofrom selectivity by umbralisib plus inhibition of CK1ε may account for some of the reduced immune-mediated toxicities observed.34,36

In a phase I dose escalation study, umbralisib showed activity in patients with a number of R/R hematologic malignancies, and 800 mg umbralisib (orally once daily) was identified as the recommended phase II dose.24 This phase IIb registration trial was designed to evaluate the efficacy and safety of daily, single-agent umbralisib 800 mg in patients with R/R iNHL.

PATIENTS AND METHODS

Trial Oversight
UNITY-NHL was conducted in accordance with applicable regulatory requirements, and the Protocol (online only) was approved by each study site’s independent ethics committee or institutional review board. Research was conducted in accordance with updated Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice Guidelines. UNITY-NHL was designed and sponsored by TG Therapeutics (New York, NY). All patients provided written informed consent. All study investigators vouch for the accuracy and completeness of reported data and analyses and confirm the trial’s adherence to the protocol (Data Supplement, online only).

Data were collected, and trial procedures were overseen by trial investigators. Data were verified by the sponsors, analyzed by sponsor statisticians, and interpreted by
academic authors and sponsor representatives. The manuscript was prepared by the authors with the assistance of a medical writer funded by the sponsors. All authors had final responsibility for content and the decision to submit for publication.

**Trial Design and Patient Eligibility**

UNITY-NHL was a phase IIb, open-label, multicohort analysis conducted at 120 sites in nine countries (Australia, Israel, Italy, Poland, Slovakia, South Korea, Spain, United Kingdom, and United States). Patients with R/R NHL were enrolled into one of the five cohorts: MZL, FL, SLL, mantle cell lymphoma, or diffuse large B-cell lymphoma. Study procedures and efficacy and safety results for MZL, FL, and SLL cohorts of the umbralisib monotherapy arm are reported here.

Eligible patients were ≥ 18 years of age and had histologically confirmed diagnosis of B-cell iNHL, subtyped based on WHO 2008 classification criteria (MZL splenic, nodal, or extranodal; FL grade 1, 2, or 3a; or SLL).1 All patients had an Eastern Cooperative Oncology Group performance status score ≤ 2. Patients with MZL were required to have had ≥ 1 prior lines of therapy, including ≥ 1 CD20-directed regimens, with failure to achieve at least partial response (PR) or with progressive disease after the most recent systemic regimen. Patients with FL or SLL were required to have relapsed or refractory disease after ≥ 2 prior lines of systemic therapy, including an anti-CD20 monoclonal antibody and an alkylating agent. All patients were required to have evidence of ≥ 1 of the following: bulky disease (> 5 cm), high lactate dehydrogenase, B symptoms, threatened organ function, splenomegaly,
cytopenias because of lymphoma, or effusions. Prophylaxis for *Pneumocystis jirovecii* pneumonia and antiviral therapy were mandated within 7 days before random assignment, which could later be discontinued at investigator discretion. Key exclusion criteria included prior anticancer therapy or any investigational drug within 21 days of day 1 of cycle 1 and prior hematologic stem-cell transplant, either autologous (within 6 months of study entry) or allogeneic (at any time). Study site information and additional inclusion or exclusion criteria are described online in the Data Supplement.

During the 28-day screening period, patients were required to undergo a fluorodeoxyglucose positron emission tomography (PET) with contrast-enhanced computed tomography (CT) scan of chest, abdomen, and pelvis (and neck, if clinically warranted). Treatment consisted of umbralisib 800 mg once daily with food on a 28-day cycle until disease progression, unacceptable toxicity, or study withdrawal. Umbralisib (TG Therapeutics) was supplied as 200 mg tablets. All patients were evaluated for response by CT, PET-CT, or magnetic resonance imaging at the end of cycle 3 and within 14 days before day 1 of cycles 6, 9, and 12. After cycle 12, response assessments occurred every 6 cycles or as clinically indicated. Patients with fluorodeoxyglucose-avid disease at screening were required to undergo PET-CT to confirm complete response (CR).

**End Points**

The primary end point was ORR, defined as the percentage of patients achieving CR or PR. Response criteria were based on the Lugano classification. Complete remission was defined as complete disappearance of all evidence of disease and disease-related symptoms; PR was defined as regression of measurable disease (≥ 50% decrease in the sum of the products of the diameters [SPD] of the index lesions coupled with no increase in size of other lymph nodes, liver, or spleen) and no new disease sites. Secondary end points included duration of response (DOR, defined as the time from documentation of a response to treatment to first documentation of tumor progression or death because of any cause, whichever comes first), progression-free survival (PFS, defined as the time from study entry to first documentation of tumor progression or death because of any cause, whichever comes first), and CR rate. Time to response (TTR, interval from enrollment to first documentation of CR or PR) was included as a post hoc analysis. Outcomes were assessed by an independent review committee (IRC); this analysis was considered primary. Investigator assessments for study end points were recorded.

Safety assessments included evaluation of adverse events (AEs), SAEs, and laboratory assessments. AE descriptions and grading scales were reported using the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 4.0. Diagnosis of colitis was based on investigator discretion. A summary of scheduled efficacy and safety assessments is provided online (Data Supplement).

**Statistical Analysis**

With a minimum of 60 patients with MZL enrolled, using a one-sided test having a 2.5% false-positive error rate to assess the null hypothesis that the IRC-reviewed ORR is 25%, the trial would have 90% power against the
alternative hypothesis that the ORR is 45%. With a minimum of 100 patients with FL, using a one-sided test having a 2.5% false-positive error rate to assess the null hypothesis that the IRC-reviewed ORR is 35%, the trial would have 90% power against the alternative hypothesis that the ORR is 51.5%. With a minimum of 25 patients with SLL and two-sided confidence intervals of the ORR derived using the Clopper-Pearson exact method, the 95% CI would be 34.9 to 75.6 for 14 responses. Futility was assessed at pre-specified timepoints, and the study was permitted to continue to full enrollment.

Efficacy and safety analyses included all patients with MZL, FL, or SLL who received ≥ 1 dose of single-agent umbralisib. The primary end point (ORR) was estimated with 95% CI by the Clopper-Pearson exact method, the 95% CI would be 34.9 to 75.6 for 14 responses. Futility was assessed at pre-specified timepoints, and the study was permitted to continue to full enrollment.

For May 2017 through September 2018, a total of 208 patients with relapsed iNHL were enrolled and treated (MZL [N = 69], FL [N = 117], and SLL [N = 22]). The intent-to-treat (ITT) cutoff date for these data was July 13, 2020. Table 1 summarizes baseline demographics and clinical characteristics for each cohort. Overall, the median age was 66 years (range, 29-88); 56.7% were male, and 81.7% were White. Of the 208 patients, 51.0% had stage IV disease; 28.4% were refractory to their last anti-CD20–based therapy. The median number of prior treatments was 2 (range, 1-10), with 46.2% of patients having received ≥ 3 prior therapies. A summary of key prior systemic therapies is shown in Table 2. All patients had received prior rituximab; the majority had received anti-CD20–based chemoimmunotherapy (75.4%, 100%, and 90.9% of patients with MZL, FL, and SLL, respectively). Some patients had received prior therapies for certain partial dates, missing data were not imputed and were treated as missing. All analyses were performed using SAS Version 9.4 or higher.
received prior bruton tyrosine kinase inhibitor (2.9% MZL, 8.5% FL, and 22.7% SLL). Twelve patients in the FL cohort had undergone autologous stem cell transplant > 6 months before study entry. Additional baseline characteristics are available online (Data Supplement).

Efficacy

With a median follow-up of 27.7 months (MZL, 27.8 months [range, 22.4-36.1]; FL, 27.5 months [20.9-37.1]; SLL, 29.3 months [22.0-33.8]), the ORR was 47.1% for the ITT population, based on IRC assessment. For patients with MZL, FL, and SLL, respectively, ORRs were 49.3% (95% CI, 37.0 to 61.6), 45.3% (95% CI, 36.1 to 54.8), and 50.0% (95% CI, 28.2 to 71.8) (Table 3). IRC assessed ORR by subgroups available online (Data Supplement). ORR was consistent across the three subtypes of MZL. CR was seen in 11 (15.9%), 6 (5.1%), and 1 (4.5%) patient with MZL, FL, and SLL, respectively. PR and stable disease (SD) rates are shown in Table 3.

The waterfall plot depicting changes in tumor volume (data for patients with ≥ 1 postbaseline radiographic assessment [n = 198]) shows that 58 of 64 (90.6%), 96 of 115 (83.5%), and 17 of 19 (89.5%) patients with MZL, FL, and SLL experienced reduction of their disease following umbralisib, respectively (Fig 1).

The median DOR was not reached for patients with MZL (95% CI, 12.1 to not estimable) and was 10.6 months (95% CI, 7.2 to 13.7) for patients with FL and 20.9 months (95% CI, 7.4 to 24.1) for patients with SLL (Fig 2). At 2 years, 50.5%, 18.1%, and 31.3% of patients with MZL, FL, and SLL remained progression free, respectively (Data Supplement).

Safety

Safety data were collected through January 1, 2020, corresponding to a median follow-up of 21.4 months (range, 14.6-30.8). The median duration of exposure for all patients was 8.4 months (range, 0.2-27.0). Patients with MZL, FL, and SLL had median durations of exposure of 9.8 months (range, 0.2-27.0), 7.6 months (range, 1.0-26.5), and 10.9 months (range, 0.7-25.1), respectively. At data cutoff, 60 patients (26, 27, and 7 with MZL, FL, and SLL, respectively) remained on treatment. Treatment-emergent AEs (TEAEs) occurring in ≥ 10% of patients are listed in Table 4. Overall, 207 of 208 patients (99.5%) experienced TEAEs, of which 53.4% had ≥ 1 grade ≥ 3 event. The most frequent TEAEs (any grade; ≥ 20% of patients) were diarrhea (59.1%), nausea (39.4%), fatigue (30.8%), vomiting (23.6%), and cough (20.7%). The majority of diarrhea events were grade 1 and typically manageable via dose holds; 46 patients (37%) received supportive care, which includes nine patients (7.3%) that received steroids.

The only grade ≥ 3 AEs that occurred in ≥ 10% of patients were neutropenia (11.5%) and diarrhea (10.1%; all grade 3). Three patients experiencing grade 3 diarrhea had colonoscopies, none of which showed signs of colitis. Other
grade 3 or 4 AEs of interest included opportunistic infections (7, 3.4%) and rash (4, 1.9%). Elevated levels of ALT and AST were observed in 20.2% (grade $^3$ in 6.7%) and 18.8% (grade $^3$ in 7.2%) of patients, respectively. Other AEs of interest included pneumonitis (1.4%; grade $^3$ 1.0%) and noninfectious colitis (1.9%; grade $^3$ 0.5%). Of the four patients experiencing noninfectious colitis, only one patient experienced overlapping diarrhea and received a colonoscopy, which revealed normal gastrointestinal morphology. Colitis resolved in three of these four patients; they remained on umbralisib.

Overall, serious TEAEs were reported in 63 patients (30.3%), with grade $^3$ serious TEAEs reported in 54 patients (26.0%). Serious TEAEs considered related to umbralisib were reported in 36 patients (17.3%). The most frequent serious TEAEs occurring in $>1$% of patients were...
TABLE 4. TEAEs (≥ 10% Overall), System Organ Class, and Preferred Term (Intent-to-Treat Population) | Total (N = 208), n (%) | Any Grade | Grade ≥ 3
---|---|---|---
Any TEAE | 207 (99.5) | 111 (53.4) | 
Hematopoietic laboratory abnormalities | | | 
Neutropenia | 33 (15.9) | 24 (11.5) | 
Any TEAE | | | 
Diarrhea | 123 (59.1) | 21 (10.1) | 
Nausea | 82 (39.4) | 1 (0.5) | 
Fatigue | 64 (30.8) | 7 (3.4) | 
Vomiting | 49 (23.6) | 1 (0.5) | 
Cough | 43 (20.7) | 0 (0.0) | 
Decreased appetite | 39 (18.8) | 4 (1.9) | 
Dizziness | 38 (18.3) | 1 (0.5) | 
Headache | 33 (15.9) | 2 (1.0) | 
Upper respiratory tract infection | 30 (14.4) | 0 (0.0) | 
Insomnia | 28 (13.5) | 1 (0.5) | 
Edema peripheral | 25 (12.0) | 1 (0.5) | 
Pyrexia | 24 (11.5) | 0 (0.0) | 
Chemical laboratory abnormality | | | 
ALT increased | 42 (20.2) | 14 (6.7) | 
AST increased | 39 (18.8) | 15 (7.2) | 
Blood creatinine increased | 29 (13.9) | 1 (0.5) | 

NOTE. Data cutoff: January 1, 2020. Abbreviation: TEAE, treatment-emergent adverse event. *Medical Dictionary for Regulatory Activities (MedDRA).

Dysregulation of the PI3K pathway plays an important role in cancer biology. Although therapeutic targeting of the pathway has produced clinical benefit for patients with iNHL, existing drugs in the class have limitations related to long-term tolerability. In this open-label, phase IIb study, oral once-daily umbralisib at a dose of 800 mg was effective in heavily pretreated patients with R/R iNHL. At a median follow-up of 27.7 months, primary study objective was met, with ORRs ranging from 45.3% to 50.0% for patients with MZL, FL, and SLL. The majority of patients (86.4%) experienced tumor size reduction with umbralisib. However, these results are similar to responses observed with first-generation PI3K inhibitors making cross-trial comparisons limited. Notably, patients included in trials for some of the first-generation PI3K inhibitors were required to be double-refractory (to both rituximab and chemotherapy that included an alkylating agent).

Umbralisib was well-tolerated, exhibiting a safety profile similar across iNHL subtypes, which was consistent with previous phase I trials evaluating umbralisib alone or in combination therapy in patients with B-cell lymphomas. In UNITY-NHL, there was a low incidence of umbralisib-related discontinuations and no deaths because of TEAEs. These data contrast with pivotal trials of first-generation PI3K inhibitors, in which investigators reported high TEAE-related discontinuation rates (up to 52%) and treatment-related deaths (3.9%-8.8%) despite shorter median follow-up times in most studies (6, 9.7, and 32 months).

First-generation oral PI3K inhibitors are associated with fatal and/or serious immune-mediated toxicities, including diarrhea and/or colitis (idelalisib, 14% to 20% and duvelisib, 18%), pneumonitis (idelalisib, 4% and duvelisib, 5%), hepatotoxicity (idelalisib, 16% to 18% and duvelisib, 2% to 8%), and fatal and/or serious infections (idelalisib, 21% to 48% and duvelisib, 31%). The first-generation intravenous pan-PI3K inhibitor, copanlisib, is associated with fatal and/or SAEs, including hypertension 26%, hyperglycemia 41%, and infection 19%. In UNITY-NHL, there was a relatively low incidence of infections and immune-mediated toxicities, including ALT/AST elevations. Although the precise mechanism for the toxicities observed with first-generation PI3K inhibitors is not yet known, attention has been focused on the individual agent’s differential PI3K isoform inhibition profile and its specific pharmacologic properties.

Given the long-term continuous dosing required for PI3K inhibitors in iNHL, identifying effective agents with safety profiles that minimize toxicity-related discontinuations is essential. Umbralisib is an effective and well-tolerated monotherapy treatment option for patients with R/R iNHL, serving as a platform for the development of novel combination regimens not enabled by currently available PI3K inhibitors. As of July 2020, more than 1,800 patients with B-cell malignancies have been treated with umbralisib, either alone or in combination with 16 other agents.
In UNITY-NHL, umbralisib showed meaningful clinical activity in patients with R/R iNHL consistent with that demonstrated by prior inhibitors of PI3K. However, the safety profile appears improved compared with first-generation PI3K inhibitors, with manageable toxicities and a relatively low number of AE-related discontinuations. These results suggest that umbralisib has a favorable benefit-risk profile in this heavily pretreated population.
4. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2020. CA Cancer J Clin 70:7-30, 2020
5. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2017. Bethesda, MD, National Cancer Institute, https://seer.cancer.gov/csr/1975-2017/
6. Denlinger NM, Epperla N, William BM: Management of relapsed/refractory marginal zone lymphoma: Focus on ibrutinib. Cancer Manag Res 10:615-624, 2018
7. National Comprehensive Cancer Network: Chronic lymphocytic leukemia/small lymphocytic lymphoma (Version 2.2021). https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf
8. National Comprehensive Cancer Network: B-Cell Lymphomas (Version 2.2021). https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
9. Morrow VA, Shou Y, Bell JA, et al: Treatment patterns and survival outcomes in patients with follicular lymphoma: A 2007 to 2015 Humedica database study. Clin Lymphoma Myeloma Leuk 15:e172-e183, 2019
10. Kritharis A, Sharma J, Evens AM: Current therapeutic strategies and new treatment paradigms for follicular lymphoma. Cancer Treat Rev 165:197-226, 2015
11. Rivas-Delgado A, Magnano L, Moreno-Velazquez M, et al: Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol 184:753-759, 2019
12. Wermer M, Hobeika E, Jumaa H: Role of PI3K in the generation and survival of B cells. Immunol Rev 237:55-71, 2010
13. Dreyling M, Santoro A, Mollica L, et al: Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 35: 3898-3905, 2017
14. Flinn IW, Miller CB, Ardeshehia KM, et al: DYNAKO: A phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 37:912-922, 2019
15. Ali K, Soond DR, Pineiro R, et al: Inactivation of PI(3)K p110alpha and CK1epsilon in hematological malignancies. Blood 134:2940-2947, 2019
16. Kahl BS, de Vos S, et al: PI3K inhibitors and their role as novel agents for targeted therapy in lymphoma. Curr Treat Options Oncol 21:191-206, 2020
17. Lampson BL, Kasar SN, Matos TR, et al: Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128:2940-2947, 2016
18. Fowler et al
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.

For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rcw or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Nathan H. Fowler
Employment: Bostongene
Consulting or Advisory Role: Roche/Genentech, TG Therapeutics, Verastem, Bayer, Celgene, Novartis
Research Funding: Roche, Celgene, Gilead Sciences, TG Therapeutics, Novartis, AbbVie, Beigene

Felipe Samaniego
Consulting or Advisory Role: Astex Pharmaceuticals, ADC Therapeutics, Imbrumar Therapeutics

Wojciech Jurczak
Research Funding: TG Therapeutics

Nilanjan Ghosh
Consulting or Advisory Role: Seattle Genetics, TG Therapeutics, AstraZeneca, Verastem, Pharmacyclics/Janssen, Karyopharm Therapeutics, Genmab, Bristol-Myers Squibb, Gilead Sciences, Adaptive Biotechnologies, Beigene, AbbVie, Incyte
Speakers’ Bureau: AbbVie, Janssen Oncology, Kite/Gilead Sciences, Seattle Genetics, AstraZeneca, Bristol-Myers Squibb, Celgene, Pharmacyclics/Janssen, Epizyme
Research Funding: Pharmacymics, TG Therapeutics, Genentech/Roche, Seattle Genetics, Bristol-Myers Squibb/Celgene, Gilead Sciences

Enrico Derenzini
Consulting or Advisory Role: AstraZeneca
Research Funding: TG-Therapeutics, ADC Therapeutics

James A. Reeves
Research Funding: Sarah Cannon Research Institute, Eli Lilly, Tesaro, TG Therapeutics, Genentech, Celgene, Merck, Bristol-Myers Squibb, Boston Biomedical Inc, AstraZeneca, NovoCure, Calithera Biosciences, Novartis, Guardant Health, Acerta Pharma, Rigel Pharmaceuticals, Takeda, Onconova Therapeutics, Sanofi, CTI Biopharma, Eisai, Janssen

Chan Y. Cheah
Honorary: Roche/Genentech, Janssen-Cilag, TG Therapeutics, Loxo/Lilly, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Ascentage Pharma, MDS
Consulting or Advisory Role: Janssen-Cilag, Roche/Genentech, TG Therapeutics, Loxo/Lilly, Gilead Sciences, AstraZeneca, Bristol-Myers Squibb, Ascentage Pharma, MDS
Speakers’ Bureau: Janssen-Cilag
Research Funding: Roche, Celgene, AbbVie
Travel, Accommodations, Expenses: Roche

Tycel Phillips
Honorary: Seattle Genetics, Incyte, Pharmacyclics, Bayer, Gilead Sciences, Genentech
Consulting or Advisory Role: Seattle Genetics, Pharmacyclics, Incyte, Genentech, Bayer, Gilead Sciences, Curis, Kite/Celgene, Genmab
Research Funding: AbbVie, Pharmacyclics/Janssen, Bayer

Ewa Lech-Maranda
Consulting or Advisory Role: Roche, Amgen, AbbVie, Astellas Pharma, Novartis, Janssen-Cilag, Sanofi/Aventis, Takeda, Gilead Sciences

Bruce D. Cheson
Consulting or Advisory Role: TG Therapeutics, AbbVie, Pharmacyclics/Janssen, Morphosys, Celgene, Karyopharm Therapeutics, Epizyme, Gilead Sciences, SyneBio Pharmaceuticals, Parexel, Merck, Glaxo Smith Kline, Beigene, Kite, Reddy Biosimilar, Bayer, Celgene
Research Funding: TG Therapeutics, Trillium Therapeutics, Seattle Genetics, Bristol-Myers Squibb, Gilead Sciences, Pharmacyclics, AbbVie, AstraZeneca
Travel, Accommodations, Expenses: SyndBio Pharmaceuticals

Paolo F. Caimi
Consulting or Advisory Role: Genentech, Seattle Genetics, TG Therapeutics, Kite Pharma, ADC Therapeutics, Bayer, Amgen, Verastem, Epizyme
Speakers’ Bureau: Celgene
Research Funding: Genentech, ADC Therapeutics

Lori A. Leslie
Consulting or Advisory Role: Kite/Gilead, TG Therapeutics, Celgene/BMS, Seattle Genetics, AbbVie, PCYC/Janssen, ADC Therapeutics, Beigene, AstraZeneca
Speakers’ Bureau: Kite Pharma, Celgene/BMS, Seattle Genetics, AbbVie, PCYC/Janssen, ADC Therapeutics, Beigene, AstraZeneca, Epizyme, Karyopharm

Julio C. Chavez
Consulting or Advisory Role: Kite/Gilead, Novartis, Karyopharm Therapeutics, MorphoSys, TeneoBio, AbbVie, Janssen
Speakers’ Bureau: AstraZeneca, Beigene, MorphoSys, Epizyme
Research Funding: Merck

Gustavo Fonseca
Honorary: Amgen, Celgene
Consulting or Advisory Role: Amgen, Celgene, Bayer, Abvie/Pharmacyclics, Dava Oncology, Karyopharm
Speakers’ Bureau: Amgen, Celgene
Research Funding: Celgene, TG Therapeutics, Verastem Oncology
Travel, Accommodations, Expenses: Amgen, Celgene

Sunil Babu
Stock and Other Ownership Interests: Fort Wayne Medical Oncology & Hematology, Lutheran Hospital
Honorary: Bristol-Myers Squibb, Alexion Pharmaceuticals, Lilly, Bayer, AstraZeneca
Consulting or Advisory Role: Bristol-Myers Squibb, Alexion Pharmaceuticals, Lilly, Bayer, AstraZeneca
Research Funding: Bristol-Myers Squibb, Alexion Pharmaceuticals

Daniel J. Hodson
Research Funding: Gilead Sciences

John M. Burke
Consulting or Advisory Role: Genentech/Roche, AbbVie, Seattle Genetics, Bayer, AstraZeneca, Adaptive Biotechnologies, Verastem, MorphoSys, Kura Oncology, Epizyme, Beigene, Kymera, Novartis
Speakers’ Bureau: Seattle Genetics, Beigene

Jeff P. Sharman
Leadership: US Oncology
Consulting or Advisory Role: Pharmacyclics, Celgene, TG Therapeutics, Genentech, AbbVie, Acerta Pharma/AstraZeneca, Beigene, Pfizer
Research Funding: Pharmacyclics, Genentech, Celgene, Acerta Pharma, Gilead Sciences, Seattle Genetics, TG Therapeutics, Merck, Takeda

John M. Pagel
Consulting or Advisory Role: Gilead Sciences, AstraZeneca, Actinium Pharmaceuticals, Beigene, Loxo

Hari P. Miskin
Employment: TG Therapeutics
Leadership: TG Therapeutics

Stock and Other Ownership Interests: TG Therapeutics
Travel, Accommodations, Expenses: TG Therapeutics

Peter Sportelli
Employment: TG Therapeutics
Leadership: TG Therapeutics

Stock and Other Ownership Interests: TG Therapeutics
Travel, Accommodations, Expenses: TG Therapeutics

AUTHORS

Umbralisib in Relapsed or Refractory Indolent Lymphoma

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rcw or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Owen A. O’Connor
Employment: TG Therapeutics
Leadership: TG Therapeutics
Board Appointments, Stock, and Other Ownership Interests: TG Therapeutics, Kymera, Myeloid Therapeutics, NomoCan Pharmaceuticals
Honoraria: Mundipharma
Consulting or Advisory Role: Mundipharma Research, Astex Pharmaceuticals
Research Funding: Merck, Celgene/Bristol-Myers Squibb, Seagen, Mundipharma, Astex Pharmaceuticals, ADC Therapeutics

Michael S. Weiss
Employment: TG Therapeutics
Leadership: TG Therapeutics
Stock and Other Ownership Interests: TG Therapeutics
Travel, Accommodations, Expenses: TG Therapeutics

Pier Luigi Zinzani
Consulting or Advisory Role: Sanofi, Verastem, Celltrion, Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, SERVIER, Sandoz, MSD, Immune Design, Celgene, Portola Pharmaceuticals, Roche, EUSA Pharma, Kyowa Hakko Kirin, TG Therapeutics, Takeda
Speakers’ Bureau: Verastem, Celltrion, Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, SERVIER, Sandoz, MSD, Immune Design, Celgene, Portola Pharmaceuticals, Roche, EUSA Pharma, Kyowa Hakko Kirin

No other potential conflicts of interest were reported.